Loading
A phase 2 trial of PM8002 in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC is a phase 2 interventional study registered as NCT05879068 by Biotheus Inc., with 99 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2025-04-30. Interventions recorded: PM8002 and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Small-cell lung cancer and the tag pipeline.
Shares PM8002, BioNTech, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/